Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Non-A non-B acute hepatitis].

C Douvin1, D Dhumeaux

  • 1Service d'hépatologie et de gastroentérologie, hôpital Henri-Mondor, Créteil.

La Revue Du Praticien
|June 21, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.

Journal of viral hepatitis·2016
Same author

Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C.

Journal of viral hepatitis·2012
Same author

The impact of the prevention programme of hepatitis C over more than a decade: the French experience.

Journal of viral hepatitis·2009
Same author

[Centenary].

Gastroenterologie clinique et biologique·2009
Same author

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

Journal of viral hepatitis·2006
Same author

Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections.

Journal of viral hepatitis·2004
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Two forms of non-A, non-B viral hepatitis are identified: hepatitis C virus (HCV) transmitted parenterally, often leading to chronic disease, and hepatitis E virus (HEV) transmitted enterically, typically causing acute illness. Vaccines for both are anticipated.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Context:

  • Non-A, non-B viral hepatitis is now classified into two distinct etiological forms.
  • Hepatitis C virus (HCV) and hepatitis E virus (HEV) are the primary causative agents.
  • Understanding their distinct transmission routes and clinical outcomes is crucial for public health.

Purpose:

  • To differentiate between parenterally transmitted non-A, non-B hepatitis (HCV) and enterically transmitted non-A, non-B hepatitis (HEV).
  • To outline the characteristics, transmission, and clinical manifestations of both HCV and HEV infections.
  • To highlight the potential for chronicity, associated risks, and future vaccine development.

Summary:

  • Hepatitis C virus (HCV) is an enveloped RNA virus transmitted parenterally, resembling Hepatitis B virus (HBV) transmission, and frequently leads to chronic hepatitis, cirrhosis, and hepatocellular carcinoma.

Related Experiment Videos

  • Hepatitis E virus (HEV) is a non-enveloped RNA virus transmitted via the fecal-oral route, similar to Hepatitis A virus (HAV), predominantly affecting developing countries and not causing chronic infection, though fulminant hepatitis can occur in pregnant women.
  • Anti-HCV antibodies are markers for chronic infection, typically absent in the acute phase, while routine serological tests for HEV are not yet established.

    • Impact:

    • Distinguishing between HCV and HEV allows for targeted prevention and treatment strategies.
    • The frequent progression of HCV to chronic liver disease underscores the need for effective antiviral therapies and preventative measures.
    • The potential development of vaccines against both HCV and HEV offers hope for future eradication and control of these significant viral hepatitis forms.